News
VALN
8.20
-7.24%
-0.64
Valneva SE Enhances R&D with New CSO Appointment
TipRanks · 10h ago
Weekly Report: what happened at VALN last week (0513-0517)?
Weekly Report · 1d ago
Valneva Seeks Expanded Use For Its Chikungunya Vaccine In Adolescents With Encouraging Phase 3 Data
Valneva SE has released further Phase 3 data in adolescents for its single-shot chikungunya virus vaccine. The vaccine is being tested on children and adolescents. The company says the vaccine is in phase 3 of a clinical trial. Valneva has a market value of $1.5 billion.
Benzinga · 05/13 16:47
Valneva Price Target Maintained With a $26.00/Share by HC Wainwright & Co.
Dow Jones · 05/13 15:30
HC Wainwright & Co. Reiterates Buy on Valneva, Maintains $26 Price Target
Benzinga · 05/13 15:23
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Valneva (VALN) and Kymera Therapeutics (KYMR)
TipRanks · 05/13 13:50
Analysts Offer Insights on Healthcare Companies: Valneva (VALN), Janux Therapeutics Inc (JANX) and Kymera Therapeutics (KYMR)
TipRanks · 05/13 13:40
VALN Stock Earnings: Valneva Misses EPS, Misses Revenue for Q1 2024
Valneva reported earnings per share of 89 cents for the first quarter of 2024. The company reported revenue of $ million. Valneva's revenue was below the analyst estimate for the same period. The stock was down 1.7% in after-hours trading.
Investorplace · 05/13 12:53
Valneva’s Chikungunya Vaccine Shows Promise in Adolescents
TipRanks · 05/13 11:28
Weekly Report: what happened at VALN last week (0506-0510)?
Weekly Report · 05/13 09:17
Cracking The Code: Understanding Analyst Reviews For Valneva
Valneva SE is a vaccine company focused on developing life-saving vaccines. In the last three months, 5 analysts have published ratings on Valneva. The company has an average 12-month price target of $24.2. The average price target is up 34.44% from the previous average of $18.00.
Benzinga · 05/08 13:00
Analysts Offer Insights on Healthcare Companies: Valneva (VALN), Denali Therapeutics (DNLI) and Armata Pharmaceuticals (ARMP)
TipRanks · 05/08 10:50
Valneva Price Target Maintained With a $26.00/Share by HC Wainwright & Co.
Dow Jones · 05/08 10:39
HC Wainwright & Co. Reiterates Buy on Valneva, Maintains $26 Price Target
Benzinga · 05/08 10:29
Valneva SE Boasts Strong Q1 2024 Performance
TipRanks · 05/07 16:59
Valneva reports Q1 results
Seeking Alpha · 05/07 10:28
Valneva For 2024 Expects Total Revenues Of €170M-€190M And R&D Investments Between €60M-€75M
2024 financial guidance confirmed. Valneva expects total revenues between €170 million and €190 million. Expected R&D investments between €60 million to €75 million, driven by the chikungunya and zika trials. Other income is expected to be between €100 million and €110 million.
Benzinga · 05/07 05:47
Valneva Q1 Revenue €32.8M Down From €33.5M YoY, Net Profit €58.9M Up From Net Loss €18.1M YoY
Benzinga · 05/07 05:46
Weekly Report: what happened at VALN last week (0429-0503)?
Weekly Report · 05/06 09:18
Weekly Report: what happened at VALN last week (0422-0426)?
Weekly Report · 04/29 09:19
More
Webull provides a variety of real-time VALN stock news. You can receive the latest news about Valneva Se through multiple platforms. This information may help you make smarter investment decisions.
About VALN
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.